| Carfilzomib | Onyx Pharma | ||
| 60 mg/Vial; Powder, Intravenous |
Less Than $1000 mn
|
||
|
More Than 5
|
More Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| Indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy | |||
|
Yes
| |||
| Kyprolis | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | **** ** ** *** ** | **** ** ** *** ** | ********* | ********* | ********* | ********* | ********* | **** ** ** | ********* | *** ********* | *** ********* |
| *** **** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ************ (*****) | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | *** ********* (***** ******) | ****** *** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** | *** \ ** | ***** **, **** | **** ** ** *** ** | **** | ***** ***-**** *********** |
| *** **** | *** \ ** | ***** **, **** | ******* | ********* ******** | ***** ***-**** *********** |
| ************ (*****) | *** \ ********* | ***** **, **** | ******* | ******** ************ | ** ** **** |
| Carfilzomib | Onyx Pharma | ||
| 30mg/vial, powder, intravenous |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
| None | None | ||
| Indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. | |||
|
Yes
| |||
| Kyprolis | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 |
|---|---|---|---|---|---|---|---|---|---|
| *** **** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ****** ****** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ********* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** **** | ** \ ** | *** **, **** | ******* | ********* ******** | ***** ***-**** *********** |
| ****** ****** | ** \ ** | *** **, **** | ******* | **** | ***** ***-**** *********** |
| ********* | ** \ ** | *** **, **** | ******* | **** | ***** ***-**** *********** |
| Carfilzomib | Onyx Pharma | ||
| 10 mg/vial; Powder, Intravenous |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| Kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy | |||
|
Yes
| |||
| Kyprolis | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ************ | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ************ | *** \ ********* | *** *, **** | ******* | ******** | ** ** **** |
Download ParaIV Report